Evidence and Value of Prescription Omega-3 Fatty Acids in Cardiovascular Disease Management - a podcast by ReachMD

CME credits: 0.25

Valid until: 31-03-2021

Claim your CME credit at https://reachmd.com/programs/cme/evidence-and-value-of-prescription-omega-3-fatty-acids-in-cardiovascular-disease-management/11291/

Despite the success of statin therapy in significantly reducing patients’ LDL-cholesterol and the risk of cardiovascular events, there remains a considerable need for event reduction. Fortunately, we now have findings from the REDUCE-IT landmark trial on icosapent ethyl that could help us find a way to meet that need.

This activity will provide practical information on the evidence, clinical utility, and use of icosapent ethyl in patients at risk of ASCVD events.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD